Literature DB >> 33082101

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.

László Urbán1, Róbert Dóczi2, Barbara Vodicska2, Dóra Tihanyi2, Magdolna Horváth3, Dóra Kormos4, István Takács5, Zsolt Pápai-Székely6, Zsuzsanna Póka-Farkas2, Edit Várkondi2, Richárd Schwáb2, Csilla Hegedüs2, István Vályi-Nagy7, István Peták8.   

Abstract

Entities:  

Keywords:  Gefitinib; Molecularly targeted therapy; NSCLC; Precision oncology; TKI

Mesh：

Substances：

Year:  2020        PMID： 33082101     DOI： 10.1016/j.cllc.2020.09.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.

Authors:  Rilan Bai; Xiao Chen; Wei Song; Huimin Tian; Jiuwei Cui
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-26       Impact factor: 4.553

Review 2.  Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations.

Authors:  Iacopo Petrini; Giuseppe Giaccone
Journal:  Onco Targets Ther       Date:  2022-10-12       Impact factor: 4.345

Review 3.  Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

Authors:  Catherine B Meador; Lecia V Sequist; Zofia Piotrowska
Journal:  Cancer Discov       Date:  2021-07-23       Impact factor: 39.397
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.